Evaxion A (EVAX) Interest Expenses (2020 - 2026)
Evaxion A's (EVAX) quarterly Interest Expenses came in at -$332000.0 in Q1 2026, up 16.37% YoY from -$285290.0 in Q1 2025, and up 87.92% on a QoQ basis from -$2.7 million in Q4 2025.
Evaxion A (EVAX) Interest Expenses (2020 - 2026) Analysis & Trends
Evaxion A (EVAX) has 7 years of Interest Expenses data on file, last reported at -$332000.0 in Q1 2026.
- Quarterly Interest Expenses rose 16.37% year-over-year to -$332000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.9 million (down 111.85% YoY) and the FY2025 annual result came in at -$5.7 million, down 83.67% from the prior year.
- Interest Expenses rose to -$332000.0 in Q1 2026, from -$2.7 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of -$158000.0 in Q1 2022 to a low of -$2.7 million in Q4 2025.
- A 5-year average of -$802823.5 and a median of -$397000.0 in 2025 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 71.59% in 2022, down 719.44% in 2022.
- Tracing EVAX's Interest Expenses over 5 years: stood at -$590000.0 in 2022, then sank by 51.69% to -$895000.0 in 2023, then surged by 48.83% to -$458000.0 in 2024, then tumbled by 500.0% to -$2.7 million in 2025, then soared by 87.92% to -$332000.0 in 2026.
- The last three Interest Expenses figures came in at -$332000.0 (Q1 2026), -$2.7 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | -332,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -332,000.00 |
| Mar 31, 2026 | -332,000.00 |
| Dec 31, 2025 | -2.75 Mn |
| Dec 31, 2025 | -2.75 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Jun 30, 2025 | -2.50 Mn |
| Jun 30, 2025 | -2.50 Mn |
| Mar 31, 2025 | -397,000.00 |
| Mar 31, 2025 | -397,000.00 |
| Dec 31, 2024 | -458,000.00 |
| Dec 31, 2024 | -458,000.00 |
| Sep 30, 2024 | -384,000.00 |
| Sep 30, 2024 | -384,000.00 |
| Jun 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -2.04 Mn |
| Mar 31, 2024 | -246,000.00 |
| Mar 31, 2024 | -246,000.00 |
| Dec 31, 2023 | -895,000.00 |
| Dec 31, 2023 | -895,000.00 |